| Name | (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid,hydrochloride |
|---|---|
| Synonyms |
2-[(2S)-2-[[(1S)-1-(Ethoxycbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecboxylicacidhydrochloride
Moexipril hydrochloride, >= SPM-925 (S)-2-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-cboxylic acid hydrochloride (3S)-2-[(2S)-2-[[(1S)-1-Ethoxycbonyl-3-Phenyl-Propyl]Amino]Propanoyl]-6,7-Dimethoxy-3,4-Dihydro-1H-Isoquinoline-3-Cboxylic Acid Hydrochloride Moexipril HydrochlorideQ: What is Moexipril Hydrochloride Q: What is the CAS Number of Moexipril Hydrochloride Q: What is the storage condition of Moexipril Hydrochloride Q: What e the applications of Moexipril Hydrochloride Moexipril HCl (RS-10085) (3S)-2-[(2S)-2-[[(1S)-1-cbethoxy-3-phenyl-propyl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-cboxylic acid hydrochloride (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-cboxylic acid hydrochloride Fempress UNII-Q1UMG3UH45 (3S)- 2-[(2S)-2-[[(1S)-1-(ethoxycbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecboxylic acid,hydrochloride (1:1) Moexipril HCl - Bio-X SPM 925 Moexipril Hydrochloride orally active,Apoptosis,Ischemic brain injury,inhibit,hatic disease,RS10085,Angiotensin-converting Enzyme (ACE),hydrochlorothiazide,essential hypertension,Moexipril hydrochloride,antihypertensive,moexiprilat,angiotensin II,cdiovasculdisease,RS 10085,Inhibitor,hypertension,Moexipril 2-[2-[[1-(ethoxycbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecboxylic acid, hydrochloride (3S)-2-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan -2-yl]amino}propanoyl]-6,7-dimethoxy-1,2,3,4-tetr ahydroisoquinoline-3-cboxylic acid hydrochloride RS-10085-197 MOEXIPRIL HYDROCHLORIDE //BP Moexipril (hydrochloride) Moexipril hydrochloride, 10 mM in DMSO Moexipril HCL 3-Isoquinolinecboxylicacid,2-[(2S)-2-[[(1S)-1-(ethoxycbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-diMethoxy-,hydrochloride (1:1), (3S) (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenyl-butan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-cboxylic acid hydrochloride Univasc (3S)-2-[(2S)-2-[[(1S)-1-(Ethoxycbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecboxylic Acid Hydrochloride UNIVASC;RS10085;RS 10085;RS-10085 RS-10085 CI-925 MOEXIPRIL HYDROCHLORIDE (3S)-2-[(2S)-2-[[(1S)-1-(Ethoxycbonyl)-3-phenyl-d5-propyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecboxylic Acid Hydrochloride Perdix Uniretic |
| Description | Moexipril HCl is a potent orally active non-sulfhydryl angiotensin converting enzyme(ACE) inhibitor, which is used for the treatment of hypertension and congestive heart failure. Target: ACEMoexipril is a long-acting ACE inhibitor suitable for once-daily administration, and like some ACE inhibitors, moexipril is a prodrug and needs to be hydrolyzed in the liver into its active carboxylic metabolite, moexiprilat, to become effective [1]. Upon oral administration of moexipril (10 mg/kg/day) to spontaneously hypertensive rats, plasma angiotensin II concentration decreased to undetectable levels, plasma ACE activity was inhibited by 98% and plasma angiotensin I concentration increased 8.6-fold 1 h after dosing. At 24 h, plasma angiotensin I and angiotensin II concentrations had returned to pretreatment levels, whereas plasma ACE activity was still inhibited by 56%. Four-week oral administration of moexipril (0.1-30 mg/kg/day) to spontaneously hypertensive rats lowered blood pressure and differentially inhibited ACE activity in plasma, lung, aorta, heart and kidney in a dose-dependent fashion [2, 3]. |
|---|---|
| Related Catalog | |
| References |
| Boiling Point | 709.3ºC at 760 mmHg |
|---|---|
| Melting Point | 141-161ºC |
| Molecular Formula | C27H35ClN2O7 |
| Molecular Weight | 535.03 |
| Flash Point | 382.8ºC |
| PSA | 114.40000 |
| LogP | 3.71510 |
| Storage condition | 2-8°C |
| Symbol |
GHS09 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H400 |
| Precautionary Statements | P273 |
| Personal Protective Equipment | Eyeshields;Gloves |
| Hazard Codes | N:Dangerous for the environment |
| Risk Phrases | R50 |
| Safety Phrases | 60 |
| RIDADR | UN 3077 |
| RTECS | NW7174500 |
|
~88%
82586-52-5 |
| Literature: Klutchko; Blankley; Fleming; Hinkley; Werner; Nordin; Holmes; Hoefle; Cohen; Essenburg Journal of Medicinal Chemistry, 1986 , vol. 29, # 10 p. 1953 - 1961 |
| Precursor 1 | |
|---|---|
| DownStream 2 | |